Defining meningitis in UK children in the conjugate vaccine era


Determining the current causes of childhood meningitis

Professor Andrew Pollard, Dr Dominic Kelly, Dr Manish Sadarangani, Dr Simon Nadel, Professor Paul Heath
Start Date
01 Oct 2012
Diagnosis and treatment
University of Oxford, UK, St Mary's Hospital, UK, St George's Hospital, University of London, UK, Oxford Radcliffe Hospitals, UK

What is this project about?

A variety of germs cause childhood meningitis, including different bacteria and viruses. Vaccines against some of the main bacteria – meningococcus C, the most common strains of pneumococcus and Haemophilus influenza type b (Hib) – are now routinely given to children in the UK, so viruses are increasingly predominant. This study will be performed across 16 major UK hospitals and will determine the current causes of childhood meningitis, including a detailed evaluation for viruses, which is not routinely done. Researchers will describe the symptoms, clinical signs and laboratory results of all children with meningitis. They will also audit the treatment these children receive in comparison with the recent NICE guideline, and determine the effects of meningitis on their health in the short- and medium-term. They will also investigate differences between children with bacterial and viral meningitis to determine how to differentiate these two groups.

Why is this important?

There is an urgent need for current data to define the features of meningitis in UK children because an understanding of the current causes, presentation and outcomes will determine whether current diagnostic methods and treatment are appropriate. For example, it is recommended that children with suspected bacterial meningitis be given steroids to prevent deafness and brain damage. However, steroids need to be given within 4 hours of antibiotics and may not be safe in viral meningitis. Since it takes longer than 4 hours to determine if the cause is bacterial or viral, the opportunity to give steroids is often lost. This project will devise a method to give doctors assurance of a bacterial diagnosis in time to treat accordingly.

The after effects of bacterial meningitis have been studied for many years, but there is very little information on the effects of viral meningitis. It is believed that most children make a full recovery, but there may be short-term effects and some small studies have suggested that language and mental development may be delayed following enteroviral meningitis in babies. The increasing proportion of non-bacterial meningitis means it is vital to describe the consequences to aid planning of appropriate follow-up of these children, and explore the potential for use of therapies to improve outcome.

Potential outcomes

The children in this study will enable future studies of long-term outcomes of childhood meningitis. The results of this study will provide a scientific basis on which to determine future priorities for health care, research and education regarding childhood meningitis. It may also identify areas requiring further research, such as treatments for non-bacterial meningitis, new supportive therapies or new vaccine targets.

Collaboration helps recruitment

Professor Pollard has joined forces with an encephalitis study run by the Liverpool Brain Infections Group, in order to help recruit as many people as possible.

The resulting partnership, called UK-ChiMES, will mean that patients eligible for both studies will only have to sign one consent form, making the whole process much quicker and more efficient. Patient samples will also be shared, meaning that children don't have to go through several procedures and costs for both studies are kept down.

Since the charity was founded in 1989, we have awarded 161 research grants. The total value of our investment in vital scientific research is over £19.1 million (€24.7 million).
We take action that benefits people directly, including training health professionals and providing support and information services.
We call for positive change as a united voice against meningitis and septicaemia, and a dedicated champion for those it affects.
We've invested nearly £20 million into meningitis research since 1989. Now, we're looking back at our most incredible achievements so far.
Give researchers the clues to help defeat meningitis
Give researchers the clues to help defeat meningitis
£160/€190/$214 decodes the genetic information in a sample of meningococcal bacteria. This information helps us to track new forms of meningitis and campaign to introduce new vaccines.
Liz Rodgers
Research Projects Manager

Hi, I’m Liz and I’m MRF's Research Projects Manager.

If you’d like to know more about this area of MRF's work, do get in touch.

Tel: 0333 405 6258